Drug Target Insights https://journals.aboutscience.eu/index.php/dti <p><strong>Drug Target Insights (DTI)</strong><em>&nbsp;</em>is an international, peer-reviewed, open access journal, covering current developments in all areas of the field of clinical therapeutics and focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes. The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life. The journal welcomes unsolicited article proposals. All articles are listed on PubMed and are freely available via PubMed Central.</p> <p>&nbsp;</p> en-US <p>Authors contributing to <strong>Drug Target Insights</strong> agree to publish their articles under&nbsp;the&nbsp;<a href="https://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener">Creative Common Attribution Non Commercial 4.0&nbsp;(CC-BY-NC 4.0)</a> license, which allows third parties&nbsp;to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.</p> lucia.steele@aboutscience.eu (Lucia Steele) silvia.minora@aboutscience.eu (Silvia Minora) Mon, 04 Jan 2021 00:00:00 +0000 OJS http://blogs.law.harvard.edu/tech/rss 60 Corticosteroid treatment reduces headache in eosinophilic meningitis: a systematic review https://journals.aboutscience.eu/index.php/dti/article/view/2197 <p class="abstract"><strong>Background:</strong> Eosinophilic meningitis (EOM) is an emerging parasitic disease that can be found worldwide, of which acute severe headache is a presenting symptom. Although such headaches may persist for up to 2 months, studies have found corticosteroid to be effective in reducing this symptom. As the most recent systematic review was published in 2015, the aim of this study was to provide a more up-to-date examination of the role of corticosteroids in EOM.</p> <p class="abstract"><strong>Methods:</strong> We included randomized controlled trials of corticosteroid treatment for EOM regardless of comparators. Research articles published in five databases were searched and evaluated. The primary outcome was headache, which was compared among various treatment regimens.</p> <p class="abstract"><strong>Results:</strong> We found a total of 257 articles after duplication removal. Of those, two met the study criteria. According to these studies, oral prednisolone alone or in a combination of albendazole resulted in fewer patients with headache after a 2-week course of treatment compared with placebo (maximum of 9.1% vs. 45.5%). The duration of headache was also shorter in the prednisolone arm vs. placebo (maximum of 5 vs. 13 days). There were no serious side effects reported.</p> <p class="abstract"><strong>Conclusion:</strong> A 2-week course of treatment with oral corticosteroid with or without albendazole reduced headaches in patients with EOM.</p> Sittichai Khamsai, Kittisak Sawanyawisuth, Vichai Senthong, Panita Limpawattana, Jarin Chindaprasirt, Pewpan M Intapan, Wanchai Maleewong, Somsak Tiamkao, Verajit Chotmongkol, Chetta Ngamjarus ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://journals.aboutscience.eu/index.php/dti/article/view/2197 Mon, 08 Mar 2021 13:42:55 +0000 Tamarind (Tamarindus indica L.) Seed a Candidate Protein Source with Potential for Combating SARS-CoV-2 Infection in Obesity https://journals.aboutscience.eu/index.php/dti/article/view/2192 <p class="abstract"><strong>Introduction:</strong> Obesity and coronavirus disease (COVID)-19 are overlapping pandemics, and one might worsen the other.</p> <p class="abstract"><strong>Methods:</strong> This narrative review discusses one of the primary mechanisms to initiate acute respiratory distress syndrome, uncontrolled systemic inflammation in COVID-19, and presents a potential candidate for adjuvant treatment. Blocking the S protein binding to angiotensin-converting enzyme 2 (ACE-2) and the 3C-like protease (3CL <sup>pro</sup>) is an effective strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.</p> <p class="abstract"><strong>Results:</strong> Host proteases such as FURIN, trypsin, and transmembrane serine protease 2 (TMPRSS) act in S protein activation. Tamarind trypsin inhibitor (TTI) shows several beneficial effects on the reduction of inflammatory markers (tumor necrosis factor α [TNF-α], leptin) and biochemical parameters (fasting glycemia, triglycerides, and very low-density lipoprotein [VLDL]), in addition to improving pancreatic function and mucosal integrity in an obesity model. TTI may inhibit the action of proteases that collaborate with SARS-CoV-2 infection and the neutrophil activity characteristic of lung injury promoted by the virus.</p> <p class="abstract"><strong>Conclusion:</strong> Thus, TTI may contribute to combating two severe overlapping problems with high cost and social complex implications, obesity and COVID-19.</p> Ana H. de A. Morais, Amanda F. de Medeiros, Isaiane Medeiros, Vanessa C.O. de Lima, Anna B.S. Luz, Bruna L.L. Maciel, Thais S. Passos ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://journals.aboutscience.eu/index.php/dti/article/view/2192 Thu, 01 Apr 2021 11:53:15 +0000